Akero Therapeutics, Inc.
AKRO
Classement en actions
#3725
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Prix de l'action
$54.65
Dernière synchronisation: 2025-12-09
Capitalisation boursière
$4.50B
Changement (1 jour)
0.00%
Changement (1 an)
1.50%
Pays
US
Échange Akero Therapeutics, Inc. (AKRO)
Catégorie
Healthcare
EPS pour Akero Therapeutics, Inc. (AKRO)
EPS au September 2025 TTM : $-3.74
Selon les derniers rapports financiers et le cours de l'action de Akero Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $-3.74. À la fin de 2023, la société avait un EPS de $-2.89 une augmentation par rapport à celui de 2022, qui était de $-2.87.
Historique de l'EPS de Akero Therapeutics, Inc. de 2017 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-3.74 | -0.27% |
| 2024 | $-3.75 | 29.76% |
| 2023 | $-2.89 | 0.70% |
| 2022 | $-2.87 | -0.69% |
| 2021 | $-2.89 | 14.68% |
| 2020 | $-2.52 | -13.10% |
| 2019 | $-2.90 | -24.68% |
| 2018 | $-3.85 | 2,306.25% |
| 2017 | $-0.16 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -563.10% |
US
|
|
| $-7.98 | 113.37% |
US
|
|
| $-5.29 | 41.44% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -841.71% |
NL
|
